Microwave ablation with immunotherapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining microwave ablation (heat treatment of tumors) with two drugs—tislelizumab (an immune-boosting drug) and docetaxel (chemotherapy)—for patients with advanced non-small cell lung cancer whose disease progressed after initial immunotherapy. The goal is to see if this combination can slow or shrink tumors better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Advanced lung cancer (stage IIIB, IIIC, or IV) confirmed by biopsy or pathology, not curable by surgery
- Previously treated with tislelizumab plus chemotherapy as first-line treatment, with disease that worsened at least 6 months after starting that treatment
- Good overall health status (able to do light daily activities with minimal assistance) and expected to live more than 6 months
- Suitable for microwave ablation procedure as determined by the study doctor
- Normal blood counts, liver, kidney, and heart function; no recent heart attacks, strokes, or serious bleeding
- Not pregnant or breastfeeding; willing to use effective birth control during and for 6 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and chemotherapy) given before and after surgery to treat stage II-IIIB non-small cell lung cancer. The goal is to see if this approach can improve outcomes for patients whose cancer can be removed surgically.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This trial tests combining microwave ablation (a procedure that uses heat to destroy tumors) with immunotherapy (drugs that help your immune system fight cancer), with or without drugs that stop blood vessel growth. The goal is to see if this combination is safe and effective for people with advanced lung or liver cancer.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.